Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study
Further secures Brii's rights in BRII-179 with full control of intellectual property, future manufacturing and supply Several combination treatment studies containing BRII-179 have quickly started to carry forward the Company's strategy for HBV functional cure DURHAM, N.C. and BEIJING, Dec. 31, ...
Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA
48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα Data from multiple combination studies sponsored by the Company and its partner continue to suppor...
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024
New translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection BRII-179 as add-on therapy induces functional antibody responses and contributes toimproved sustained HBsAg loss in PEG-IFNa-t...
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies
DURHAM, N.C. and BEIJING, May 14, 2024 /PRNewswire/ -- Brii Biosciences Limited
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding it...
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and royalty payments to VBI, subject to achievement of certain activities Transferring manufacturing technologies of BRII-179 and PreHevbrio/PreHevbri to additional manufacturing sites and expanding footp...
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
DURHAM, N.C., and BEIJING, Jan. 3, 2024 /PRNewswire/ -- Brii Biosciences Limited
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023
Direct evidence that BRII-179-induced functional antibody responses can contribute to increased and sustained HBsAg loss rate New insight in utilizing BRII-179 to enriching patients with intrinsic humoral immune responses for higher HBsAg loss or HBV functional cure rates New data support ...
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023
Direct evidence that BRII-179-induced functional antibody responses can contribute to increased and sustained HBsAg loss rate New insight in utilizing BRII-179 to enriching patients with intrinsic humoral immune responses for higher HBsAg loss or HBV functional cure rates New data support ...
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
BRII-179 (VBI-2601) as an add-on therapy to standard of care PEG-IFNα increases HBsAg loss rate at the end of treatment and 12 weeks follow up Significantly increased HBsAg seroconversion rate is strongly associated with BRII-179 treatment and correlates with the increased rate of HBsAg loss Saf...
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in enriching patients with strong intrinsic anti-HBsAg responses for curative treatments to start before the end ...
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure
Extension of BRII-179 license from VBI Vaccines to global rights bolsters Brii Bio's position to achieve best-in-class HBV functional cure in broad patient populations Company also acquires exclusive rights to PreHevbri®, a clinically differentiated, 3-antigen prophylactic vaccine, from VBI inGr...
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsA...
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023
Late-breaking data from BRII-835 + PEG-IFN-a study demonstrate anti-HBs titers at the end of treatment were associated with sustained HBsAg loss 24 weeks after the end of treatment New data show more robust and persistent anti-HBs titers following vaccination with VBI's 3-antigen prevention vac...
Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders
BRII-297, a first-of-its-kind treatment option for anxiety and depressive
disorders, has the potential to enable greater therapeutic adherence and
convenience for patients
DURHAM, N.C. and BEIJING, June 1, 2023 /PRNewswire/ -- Brii Biosciences
Limited
Brii Bio Publishes 2022 Environmental, Social and Governance Report
Brii Bio receives an "A" grade in the latest MSCI ESG Rating
DURHAM, N.C. and BEIJING, April 28, 2023 /PRNewswire/ -- Brii Biosciences
Limited
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results
Company maintains priority focus on clinical programs to develop a novel f unctional cure for hepatitis B viral (HBV) infection and a potential first-of-its-kind treatment for postpartum depression (PPD) and major depressive disorders (MDD) Multiple Phase 2a proof-of-concept (POC) clinical data r...
Brii Biosciences Provides Update on Strategic Clinical Development Progress
Topline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination studies expected in the first half of 2023 Initiation of Phase 2 postpartum depression (PPD) study planned for early 2023 to advance potential first-of-its-kind treatment U.S. FDA lifted clinical hol...
Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
* Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated * Results indicate potential for oral once-weekly, long-acting combination therapy for HIV infection, supporting continued clinical development * Additional data presented by Brii's licensing part...
Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression
* Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable pharmacokinetic profile and is safe and well-tolerated in healthy subjects * Findings suggest BRII-296 has potential to provide a safe and effective, one-time injectable treatment option to people wit...
